Induction of humoral immune responses and inhibition of metastasis in mice by a VEGF peptide-based vaccine

Publish Year: 1398
نوع سند: مقاله ژورنالی
زبان: English
View: 365

This Paper With 8 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_IJBMS-23-4_012

تاریخ نمایه سازی: 27 مرداد 1399

Abstract:

Objective(s): Blocking of vascular endothelial growth factor (VEGF) plays a pivotal role in inhibition of metastasis and is a target for development of anti-angiogenic agents. In this study, a peptide-based vaccine was designed and its potential for induction of humoral immune responses, generation of neutralizing antibodies, inhibition of tumor growth and metastasis was determined.Materials and Methods: With online bioinformatics tools, a fragment of the VEGF-A was selected for a peptide-based vaccine. To enhance its antigenicity, the peptide was conjugated with Keyhole limpet hemocyanin and used to immunize mice. Then, the polyclonal anti-VEGF antibody titer was measured and its effect on proliferation of HUVEC cell line was investigated by MTT assay. Finally, we checked the effect of the peptide on tumor growth, metastasis, and survival rates in a mouse model of cancer.Results: The bioinformatics analysis of the selected region confirmed dis-similarity of the peptide with any other human protein and its acceptable antigenicity to stimulate a tumor-specific humoral response. Anti-VEGF antibody titers were significantly greater in vaccinated mice than in controls. IgG antibody from mice immunized with recombinant VEGF-A inhibited HUVEC proliferation (P<0.0001). Tumors in vaccinated mice were significantly smaller than those in controls. Moreover, metastasis was reduced and survival rates increased in the vaccinated group.Conclusion: Production of high-titer antibody against the peptide vaccine indicated that the peptide has the potency to be used as a peptide-based vaccine for humoral inhibition of tumor growth and metastasis. The efficacy of the peptide should be further tested in primate models.

Authors

Faezeh Soltanpour Gharibdousti

Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran|Immunology Research Center, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

Banafsheh Fazeli Delshad

Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran|Immunology Research Center, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

Reza Falak

Immunology Research Center, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

Nasrin Shayanfar

Department of Pathology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
  • Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med ...
  • Ramjiawan RR, Griffioen AW, Duda DG. Anti-angiogenesis for cancer revisited: ...
  • Tugues S, Koch S, Gualandi L, Li X, Claesson-Welsh L. ...
  • Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of ...
  • Woolard J, Bevan HS, Harper SJ, Bates DO. Molecular diversity ...
  • Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. ...
  • Heath VL, Bicknell R. Anticancer strategies involving the vasculature. Nature ...
  • Kong DH, Kim MR, Jang JH, Na HJ, Lee S. ...
  • Matrana MR, Atkinson B, Jonasch E, Tannir NM. Emerging targeted ...
  • Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, ...
  • Emens LA. Cancer vaccines: on the threshold of success. Expert ...
  • Berzofsky JA, Oh S, Terabe M. Peptide vaccines against cancer. ...
  • Morera Y, Bequet-Romero M, Ayala M, Lamdan H, Agger EM, ...
  • Morera Y, Bequet-Romero M, Ayala M, Perez PP, Castro J, ...
  • Okaji Y, Tsuno NH, Saito S, Yoneyama S, Tanaka M, ...
  • Gavilondo JV, Hernandez-Bernal F, Ayala-Avila M, de la Torre AV, ...
  • Soltanpour-Gharibdousti F, Kardar GA, Fazeli-Delshad B, Falak R, Ganjalikhani-Hakemi M, ...
  • Soukhtanloo M, Falak R, Sankian M, Varasteh AR. Generation and ...
  • Fazeli-Delshad B, Ganjalikhani-Hakemi M, Soltanpour-Gharibdousti F, Shayanfar N, Falak N, ...
  • Briand JP, Muller S, Van Regenmortel MHV. Synthetic peptides as ...
  • Zegers N, Gerritse K, Deen C, Boersma W, Claassen E. ...
  • Swain M, Ross NW. A silver stain protocol for proteins ...
  • Ichihara E, Kiura K, Tanimoto M. Targeting Angiogenesis in Cancer ...
  • Bellou S, Pentheroudakis G, Murphy C, Fotsis T. Anti-angiogenesis in ...
  • Suzuki H, Fukuhara M, Yamaura T, Mutoh S, Okabe N, ...
  • Vacchelli E, Martins I, Eggermont A, Fridman W, Galon J, ...
  • Wei YQ, Huang MJ, Yang L, Zhao X, Tian L, ...
  • Kamstock D, Elmslie R, Thamm D, Dow S. Evaluation of ...
  • Rad FH, Le Buanec H, Paturance S, Larcier P, Genne ...
  • Morera Y, Bequet-Romero M, Ayala M, Velazco JC, Perez PP, ...
  • Morera Y, Gonzalez R, Lamdan H, Perez L, Gonzalez Y, ...
  • Vicari D, Foy KC, Liotta EM, Kaumaya PT. Engineered conformation-dependent ...
  • Wang B, Kaumaya PT, Cohn DE. Immunization with synthetic VEGF ...
  • Kyutoku M, Nakagami H, Koriyama H, Tomioka H, Nakagami F, ...
  • Pulaski BA, Ostrand-Rosenberg S. Reduction of established spontaneous mammary carcinoma ...
  • Lelekakis M, Moseley JM, Martin TJ, Hards D, Williams E, ...
  • Mawalla B, Yuan X, Luo X, Chalya PL. Treatment outcome ...
  • Wada S, Yada E, Ohtake J, Sasada T. Personalized peptide ...
  • Vreeland TJ, Hale DK, Clifton GT, Sears AK, Mittendorf EA ...
  • نمایش کامل مراجع